Mounjaro Cardiovascular Risk Reduction

Trial Proves Mounjaro Cuts Heart Risk by 8%

The SURPASS-CVOT trial enrolled 13,299 participants across 640 sites in 30 countries to test Mounjaro head-to-head against Trulicity. Market Screener Mounjaro reduced the composite outcome of cardiovascular death, heart attack, and stroke by roughly 8% versus Trulicity, achieving non-inferiority on the primary endpoint. While statistical superiority over Trulicity was not established, the data convinced the FDA that Mounjaro delivers real heart protection.

Kenneth Custer, an executive vice president at Lilly, emphasized the stakes: "For people with type 2 diabetes, heart disease is the leading cause of death, and Mounjaro now gives them a proven way to lower that risk." StockTwits This makes Mounjaro a dual-benefit drug—controlling blood sugar while guarding against the No. 1 killer of diabetics.

2 sources

How Mounjaro's Dual Mechanism Powers Results

Mounjaro works differently than older diabetes drugs. It activates both GIP and GLP-1 receptors in a single molecule, creating a one-two punch against high blood sugar and excess weight. TradingView This combined approach helps patients lose weight, control blood sugar, and now—according to the trial data—reduce heart attack and stroke risk. No other diabetes drug on the market combines both mechanisms in this way.

1 source

Mounjaro Crushes Revenue Records Amid Expansion

Mounjaro is already one of Eli Lilly's fastest-growing drugs. U.S. revenue jumped 45% to $4.8 billion in the most recent quarter, and total annual revenue now approaches $9–9.9 billion. Yahoo Finance The cardiovascular approval removes a key barrier to wider adoption by giving doctors and insurers confidence that the drug prevents serious health events, not just lowers A1C numbers.

1 source

Competition Heats Up in GLP-1 Cardiovascular Race

Novo Nordisk's Wegovy won FDA clearance for cardiovascular risk reduction in a specific heart-disease population in 2024, signaling that GLP-1 drugs are becoming standard heart-disease prevention tools. Market Screener Lilly is now aggressively pursuing additional cardiovascular indications for its pipeline. The expanded Mounjaro label puts pressure on rivals to demonstrate similar benefits and opens a new front in the growing competition over which GLP-1 therapy best protects the heart.

1 source